Actinium Pharmaceuticals, Inc. Form 8-A12B March 24, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

ACTINIUM PHARMACEUTICALS. INC. (Exact name of registrant as specified in its charter)

Delaware 88-0378336

(State of incorporation or organization) (I.R.S. Employer Identification No.)

501 Fifth Avenue, 3rd Floor
New York, NY
10017
(Address of principal executive offices)
(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered Common stock, \$0.001 par value per share Name of each exchange on which each class is to be registered NYSE MKT LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A(d), check the following box. o

Securities Act registration statement file number to which this form relates: Form S-1, File No. 333-187313

Securities to be registered pursuant to Section 12(g) of the Act:

None (Title of Class)

Edgar Filing: Actinium Pharmaceuticals, Inc. - Form 8-A12B

Item 1.
Description of
Registrant's
Securities
to be
Registered.

Actinium Pharmaceuticals, Inc. (the "Registrant") hereby incorporates by reference the description of its common stock, par value \$0.001 per share, to be registered hereunder contained under the heading "Description of Securities" in the Registrant's Registration Statement on Form S-1 (File No. 333-187313), as initially filed with the Securities and Exchange Commission (the "Commission") on March 15, 2013, as subsequently amended (the "Registration Statement"), and in the prospectus included in the Registration Statement filed separately by the Registrant with the Commission on November 19, 2013 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

Item 2. Exhibits.

In accordance with the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on the NYSE MKT LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

ACTINIUM PHARMACEUTICALS, INC.

Date: March 24, 2014 By: /s/ Kaushik J. Dave

Kaushik J. Dave

President & Chief Executive

Officer